XML 143 R43.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Investments (Details Narrative) - USD ($)
 12 Months Ended
Jul. 22, 2021
Mar. 18, 2021
Mar. 15, 2021
Jan. 01, 2021
Dec. 19, 2020
Dec. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Apr. 01, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross           10,574,000      
Stock Purchase Agreement [Member] | Impact Oncology PTE Ltd [Member]                  
Ordinary shares to purchase   2,480,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross   250,000              
Business Combination, Consideration Transferred   $ 2,480,000              
Stock Purchase Agreement [Member] | Vivacitas Oncology Inc [Member]                  
Ordinary shares to purchase     500,000            
Shares Issued, Price Per Share     $ 1.00           $ 1.00
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross     1,500,000            
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price     $ 1.00            
Share-Based Compensation Arrangement by Share-Based Payment Award, Description     This option will terminate upon one of the following events: (i) Vivacitas’ board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company’s common stock in a private placement with gross proceeds of $            
Proceeds from Issuance of Private Placement     $ 500,000            
Proceeds from Issuance of Common Stock             $ 120,000    
Vivacitas Agreement [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period 1,000,000                
Stock Issued During Period, Value, Stock Options Exercised $ 1,000,000                
Increasing percentage of equity investment, rate               16.00%  
Investment Owned, Net Assets, Percentage               100.00%  
Investment Owned, Cost               $ 4,100,000  
BioMed Technologies Asia Pacific Holdings Limited [Member] | Subscription Arrangement [Member]                  
Ordinary shares to purchase         525        
Ordinary shares, percentage         4.99%        
Stock Issued During Period, Value, New Issues         $ 632,000        
Nano9, LLC. [Member] | Securities Purchase Agreement [Member]                  
Ordinary shares to purchase       1,000          
Stock Issued During Period, Value, New Issues       $ 150,000          
Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest       10.00%